The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.

ABSTRACT:

Objective

To assess the short term safety of the COVID-19 vaccines Comirnaty (Pfizer-BioNTech BNT162b2) and Vaxzevria (AstraZeneca ChAdOx1) in Australia.

Design

Prospective observational cohort study; online surveys by AusVaxSafety, a national active vaccine safety surveillance system, three and eight days after vaccination.

Setting, participants

People aged 16 years or more who received COVID-19 vaccines at sentinel vaccination hubs, general practices, or Aboriginal Community Controlled Health Organisation clinics, 22 February - 30 August 2021.

Main outcome measures

Primary outcome: proportion of respondents who reported any adverse event following immunisation (AEFI) 0-3 days after vaccination.

Secondary outcomes

proportions of respondents who reported

SUBMITTER: Deng L 

PROVIDER: S-EPMC9350119 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature